Metabolic Adaptations to MEK and CDK4/6 Cotargeting in Uveal Melanoma
暂无分享,去创建一个
A. Aplin | J. Aguirre-Ghiso | J. Teh | Takami Sato | Vivian Chua | Prem S. Patel | Timothy J. Purwin | Anna Han | Usman Baqai | M. Davies | Connie Liao | Nelisa Bechtel
[1] R. Deberardinis,et al. A Novel Mitochondrial Inhibitor Blocks MAPK Pathway and Overcomes MAPK Inhibitor Resistance in Melanoma , 2019, Clinical Cancer Research.
[2] Michael L. Wang,et al. Metabolic reprogramming toward oxidative phosphorylation identifies a therapeutic target for mantle cell lymphoma , 2019, Science Translational Medicine.
[3] G. Schwartz,et al. Stromal fibroblast growth factor 2 reduces the efficacy of bromodomain inhibitors in uveal melanoma , 2019, EMBO molecular medicine.
[4] A. Aplin,et al. Effects of Oncogenic Gαq and Gα11 Inhibition by FR900359 in Uveal Melanoma , 2018, Molecular Cancer Research.
[5] M. Protopopova,et al. An inhibitor of oxidative phosphorylation exploits cancer vulnerability , 2018, Nature Medicine.
[6] M. Keating,et al. Biological and metabolic effects of IACS-010759, an OxPhos inhibitor, on chronic lymphocytic leukemia cells , 2018, Oncotarget.
[7] R. Dummer,et al. In Vivo E2F Reporting Reveals Efficacious Schedules of MEK1/2-CDK4/6 Targeting and mTOR-S6 Resistance Mechanisms. , 2018, Cancer discovery.
[8] J. McCubrey,et al. Drug discovery targeting the mTOR pathway. , 2018, Clinical science.
[9] C. Berking,et al. Selumetinib in Combination With Dacarbazine in Patients With Metastatic Uveal Melanoma: A Phase III, Multicenter, Randomized Trial (SUMIT). , 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[10] M. Goetz,et al. MONARCH 3: Abemaciclib As Initial Therapy for Advanced Breast Cancer. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[11] P. Fortina,et al. Establishment of an orthotopic patient-derived xenograft mouse model using uveal melanoma hepatic metastasis , 2017, Journal of Translational Medicine.
[12] C. Berking,et al. Phase 1b/2 trial of ribociclib+binimetinib in metastatic NRAS-mutant melanoma: Safety, efficacy, and recommended phase 2 dose (RP2D). , 2017 .
[13] A. Aplin,et al. Dysregulated GPCR Signaling and Therapeutic Options in Uveal Melanoma , 2017, Molecular Cancer Research.
[14] A. Aplin,et al. Co-targeting HGF/cMET Signaling with MEK Inhibitors in Metastatic Uveal Melanoma , 2017, Molecular Cancer Therapeutics.
[15] K. Gelmon,et al. Palbociclib and Letrozole in Advanced Breast Cancer. , 2016, The New England journal of medicine.
[16] A. Aplin,et al. An In Vivo Reporter to Quantitatively and Temporally Analyze the Effects of CDK4/6 Inhibitor-Based Therapies in Melanoma. , 2016, Cancer research.
[17] A. Bowcock,et al. Driver Mutations in Uveal Melanoma: Associations With Gene Expression Profile and Patient Outcomes. , 2016, JAMA ophthalmology.
[18] E. Knudsen,et al. Metabolic Reprogramming of Pancreatic Cancer Mediated by CDK4/6 Inhibition Elicits Unique Vulnerabilities. , 2016, Cell reports.
[19] J. Mesirov,et al. The Molecular Signatures Database Hallmark Gene Set Collection , 2015 .
[20] J. Sosman,et al. 3300 A phase 1b/2 study of ribociclib (LEE011; CDK4/6 inhibitor) in combination with binimetinib (MEK162; MEK inhibitor) in patients with NRAS-mutant melanoma , 2015 .
[21] N. Dhomen,et al. Resistance to BRAF inhibitors induces glutamine dependency in melanoma cells , 2015, Molecular oncology.
[22] A. Aplin,et al. Paracrine Effect of NRG1 and HGF Drives Resistance to MEK Inhibitors in Metastatic Uveal Melanoma. , 2015, Cancer research.
[23] Alexander Lorz,et al. Emergence of drug tolerance in cancer cell populations: an evolutionary outcome of selection, nongenetic instability, and stress-induced adaptation. , 2015, Cancer research.
[24] G. McArthur,et al. Cell cycle control as a promising target in melanoma , 2015, Current opinion in oncology.
[25] Kakajan Komurov,et al. Inhibition of mTORC1/2 overcomes resistance to MAPK pathway inhibitors mediated by PGC1α and oxidative phosphorylation in melanoma. , 2014, Cancer research.
[26] W. Huber,et al. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2 , 2014, Genome Biology.
[27] G. Linette,et al. Effect of selumetinib vs chemotherapy on progression-free survival in uveal melanoma: a randomized clinical trial. , 2014, JAMA.
[28] Kang Zhang,et al. Mutant Gq/11 promote uveal melanoma tumorigenesis by activating YAP. , 2014, Cancer cell.
[29] J. Sosman,et al. A phase 1b/2 study of LEE011 in combination with binimetinib (MEK162) in patients with NRAS-mutant melanoma: Early encouraging clinical activity. , 2014 .
[30] H. Rui,et al. Expression of insulin‐like growth factor‐1 receptor in metastatic uveal melanoma and implications for potential autocrine and paracrine tumor cell growth , 2014, Pigment cell & melanoma research.
[31] Jun S. Song,et al. Oncogenic BRAF regulates oxidative metabolism via PGC1α and MITF. , 2013, Cancer cell.
[32] P. Puigserver,et al. PGC1α expression defines a subset of human melanoma tumors with increased mitochondrial capacity and resistance to oxidative stress. , 2013, Cancer cell.
[33] Edgar Brunner,et al. Nonparametric analysis of longitudinal data in factorial experiments , 2012 .
[34] Gerald C. Chu,et al. Oncogenic NRAS signaling differentially regulates survival and proliferation in melanoma , 2012, Nature Medicine.
[35] Rohan Shah,et al. dlmap: An R Package for Mixed Model QTL and Association Analysis , 2012 .
[36] Colin N. Dewey,et al. RSEM: accurate transcript quantification from RNA-Seq data with or without a reference genome , 2011, BMC Bioinformatics.
[37] J. O'Brien,et al. Mutations in GNA11 in uveal melanoma. , 2010, The New England journal of medicine.
[38] Ben S. Wittner,et al. A Chromatin-Mediated Reversible Drug-Tolerant State in Cancer Cell Subpopulations , 2010, Cell.
[39] Pablo Tamayo,et al. Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles , 2005, Proceedings of the National Academy of Sciences of the United States of America.
[40] J. Lyons,et al. Recent progress in targeting the Raf/MEK/ERK pathway with inhibitors in cancer drug discovery. , 2005, Current opinion in pharmacology.
[41] M. Daly,et al. PGC-1α-responsive genes involved in oxidative phosphorylation are coordinately downregulated in human diabetes , 2003, Nature Genetics.
[42] Subir Ghosh,et al. Nonparametric Analysis of Longitudinal Data in Factorial Experiments , 2003, Technometrics.
[43] Alexander V Penson,et al. Integrative Analysis Identifies Four Molecular and Clinical Subsets in Uveal Melanoma. , 2018, Cancer cell.
[44] J. Mesirov,et al. The Molecular Signatures Database (MSigDB) hallmark gene set collection. , 2015, Cell systems.
[45] Xin Huang,et al. The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study. , 2015, The Lancet. Oncology.
[46] Thomas R. Gingeras,et al. STAR: ultrafast universal RNA-seq aligner , 2013, Bioinform..
[47] G. Barsh,et al. Frequent somatic mutations of GNAQ in uveal melanoma and blue naevi , 2010 .
[48] Edgar Brunner,et al. Nonparametric methods in factorial designs , 2001 .
[49] R. Scully,et al. Assessment of metastatic disease status at death in 435 patients with large choroidal melanoma in the Collaborative Ocular Melanoma Study (COMS): COMS report no. 15. , 2001, Archives of ophthalmology.